Arecor Ltd , the UK-based leading formulation technology company, today announces that its abstract supporting the application of its proprietary Arestat™ technology platform to enable a superfast insulin product has been accepted for a poster presentation at the upcoming American Diabetes Association (ADA) 78th Scientific Sessions, from June 22 - 26, 2018 in Orlando, FL, USA.
Arecor announces superfast insulin data presentations at ADA scientific sessions
During this meeting, Professor Thomas Pieber, a key member of Arecor’s Scientific Advisory Board, will present a poster detailing the pre-clinical results of Arecor’s superfast insulin.
“We are very pleased to be presenting details of our proprietary superfast insulin programme for the first time at this year’s ADA Scientific Sessions and to an international audience of experts dedicated to improving the life of people with diabetes. These results further confirm the potential of our proprietary formulation technology to deliver a next generation superfast acting insulin and to improve the treatment options and quality of life of people living with diabetes,” commented Dr Sarah Howell, Chief Executive Officer of Arecor.
POSTER # 95-LB: Pharmacokinetic and Pharmacodynamic Properties of a Novel "Superfast" Insulin AspartFormulation
Presenting Author: Professor Thomas Pieber
Date and time: Monday June 25, 2018 12:00 PM – 01:00 PM
Location: WA4-WB2 (Poster Hall)
About the ADA Scientific Sessions
The American Diabetes Association’s Scientific Sessions offers researchers and health care professionals around the world an exclusive opportunity to share ideas and gain knowledge about the recent advances in diabetes research, treatment, and care. Attendees will have access access to more than 2,800 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, and expand their professional networks. For further information, please email: email@example.com
Arecor Limited, located on the Cambridge Science Park, was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.